Uses of gallocatechin

• US 10,646,466 B2
• Filed: 11/06/2018
• Issued: 05/12/2020
• Est. Priority Date: 11/22/2017
• Status: Active Grant

• Current Assignee: TCI CO., LTD
• Original Assignee: TCI CO., LTD
• Inventors: Lin, Yung-Hsiang, Yu, Chin-Hsiu, Su, Yu-Hung, Lin, Shan-Yu, Chung, Yu-Ming
• Primary Examiner(s): Jean-Louis, Samira J
• Application Number:
  US16/182,158
• Publication Number:
  US 20190151281A1
• Time in Patent Office: 553 Days
• CPC Class Codes: A61K 31/122 having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
• CPC Class Codes: A61K 31/353 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0053 Mouth and digestive tract, i.e. intraoral and peroral administration rectal administration A61K9/0031
• CPC Class Codes: A61P 25/20 Hypnotics; Sedatives

Abstract

A method for at least one of increasing the synthesis of melatonin and promoting the secretion of melatonin is provided, wherein the method comprises administering to a subject in need an effective amount of a compound of formula (I):

A method for at least one of treating diseases related to neurometabolic disorder, preventing diseases related to neurometabolic disorder, regulating appetite, regulating mood, regulating vasoconstriction, regulating hemostatic function and regulating immune response is also provided, wherein the method comprises administering to a subject in need an effective amount of a compound of formula (I) as described above.

Claims

1. A method for increasing synthesis of melatonin consisting of administering to a subject in need an effective amount of a composition consisting of (i) a compound of formula (I):

2. The method as claimed in claim 1, wherein the composition is administered to the subject by at least one of oral administration, transdermal administration, intravenous injection, and subcutaneous injection.

3. The method as claimed in claim 1, which is for at least one of treating insomnia, ameliorating sleep disturbance and regulating sleep.

4. The method as claimed in claim 1, which is for treating insomnia.

5. The method as claimed in claim 1, which is for at least one of ameliorating sleep disturbance and regulating sleep.

6. The method as claimed in claim 4, wherein the composition is administered to the subject by at least one of oral administration, transdermal administration, intravenous injection, and subcutaneous injection.

7. The method as claimed in claim 5, wherein the composition is administered to the subject by at least one of oral administration and transdermal administration.

8. The method as claimed in claim 1, which is for at least one of increasing expression of TPH1 gene, increasing expression of DDC gene, increasing expression of AANAT gene and increasing expression of ASMTL gene, therefore, increasing synthesis of melatonin.

9. The method as claimed in claim 8, wherein the composition is administered to the subject by at least one of oral administration, transdermal administration, intravenous injection, and subcutaneous injection.